Abstract
Heart failure (HF) is associated with high morbidity, mortality and significant excess financial expenditure. Dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, has shown the benefit in lowering the risk of worsening heart failure or death from cardiovascular (CV) causes in heart failure with reduced ejection fraction (HFrEF) patients compared with placebo. This analysis estimated medical costs differences among HFrEF patients treated with dapagliflozin versus placebo, in addition to recommended therapy in China.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
